HOWL Werewolf Therapeutics Inc

Price (delayed)

$0.9894

Market cap

$48.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.72

Enterprise value

$26.1M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 37

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary ...

Highlights
Werewolf Therapeutics's debt has shrunk by 100% QoQ and by 100% YoY
HOWL's EPS has soared by 56% YoY and by 40% from the previous quarter
The quick ratio has surged by 131% since the previous quarter but it has declined by 46% year-on-year
The equity has plunged by 61% YoY but it has grown by 34% from the previous quarter

Key stats

What are the main financial stats of HOWL

HOWL stock price

How has the Werewolf Therapeutics stock price performed over time
Intraday
0.75%
1 week
7.66%
1 month
13.27%
1 year
-44.73%
YTD
56.18%
QTD
174.91%

Financial performance

How have Werewolf Therapeutics's revenue and profit performed over time
Revenue
$21M
Gross profit
$21M
Operating income
-$31.26M
Net income
-$34.61M
Gross margin
100%
Net margin
-164.8%
Werewolf Therapeutics's operating income has surged by 57% YoY and by 44% QoQ
The company's net income has surged by 53% YoY and by 38% QoQ

Price vs fundamentals

How does HOWL's price correlate with its fundamentals

Growth

What is Werewolf Therapeutics's growth rate over time

Valuation

What is Werewolf Therapeutics stock price valuation
P/E
N/A
P/B
2.95
P/S
2.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.24
HOWL's EPS has soared by 56% YoY and by 40% from the previous quarter
HOWL's price to book (P/B) is 109% higher than its 5-year quarterly average of 1.4 and 33% higher than its last 4 quarters average of 2.2
The equity has plunged by 61% YoY but it has grown by 34% from the previous quarter

Efficiency

How efficient is Werewolf Therapeutics business performance
Werewolf Therapeutics's return on equity has decreased by 49% YoY but it has increased by 20% QoQ
HOWL's ROIC is down by 35% YoY and by 8% QoQ
Werewolf Therapeutics's return on assets has increased by 20% QoQ and by 4.5% YoY

Dividends

What is HOWL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOWL.

Financial health

How did Werewolf Therapeutics financials performed over time
The quick ratio has surged by 131% since the previous quarter but it has declined by 46% year-on-year
HOWL's current ratio has surged by 129% since the previous quarter but it is down by 45% year-on-year
Werewolf Therapeutics's debt is 100% lower than its equity
Werewolf Therapeutics's debt has shrunk by 100% QoQ and by 100% YoY
HOWL's debt to equity has plunged by 100% from the previous quarter and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.